Biotech and Pharmaceuticals Pharmaceuticals

  • Zeroing in on rising drug prices

    CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.

  • Positive market signals

    Discussing the best stocks and sectors to own right now, with Peter Costa, Empire Executions, and David Darst, Morgan Stanley Wealth Management.

  • Big move for PTC Therapeutics

    PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.

  • Drug pricing in US versus world

    CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.

  • Ataluren drives PTC Therapeutics

    CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.

  • Why Sovaldi is expensive

    CNBC's Meg Tirrell provides insight to why the price of Gilead's hepatitis C Sovaldi appears high.

  • Fighting back on drug prices

    CNBC's Bertha Coombs reports Express Scripts senior vice president and CMO Dr. Steve Miller has rallied a coalition of insurers and health plan providers to play hard ball with drug maker Gilead for a discount on its new hepatitis C drug.

  • High prescription drug prices

    CNBC's Meg Tirrell compares the value versus the price for Gilead's hepatitis C Sovaldi.

  • When drug costs become too cheap

    CNBC biotech and pharmaceutical reporter Meg Tirrell discusses what happens on the flip-side of high health-care costs—when antibiotic costs become too low and stifle development.

  • When drugs get too cheap

    CNBC's Meg Tirrell reports antibiotics cost much less than drugs for chronic or rare diseases. The FMHR traders discuss the consequences of when drugs get too cheap.

  • Instead of criticizing foreign deals, we should be talking about corporate-tax reform to bring business—and jobs—back to the US, says Jake Novak.

  • Pfizer deal 'wounded,' not dead: Analyst

    AstraZeneca told Pfizer its final offer isn't good enough. Mark Schoenebaum, ISI Group biotech & pharma analyst, provides insight to the potential deal.

  • As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.

  • Price is not the only criteria: AstraZeneca chair

    Execution risk and the disruptive element of Pfizer's offer on AstraZeneca's pipeline were also taken into consideration before rebuffing the U.S. giant, Leif Johansson, chairman at AstraZeneca, tells CNBC.

  • Bill Ackman

    Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.

  • AstraZeneca rejects Pfizer's 'best & final'

    AstraZeneca has rejected Pfizer's final offer of about $117,000 billion. CNBC's Meg Tirrell says the drug maker has no plans to go hostile.

  • AstraZeneca had 'strong feedback' from shareholders: Chair

    Leif Johansson, AstraZeneca's chairman, says the group engaged with shareholders before rejecting Pfizer's offer and included their price conditions for a deal after "very strong feedback" from shareholders.

  • An employee of British drug firm GlaxoSmithKline (GSK) enters their office headquarters in Shanghai.

    Chinese police have charged several former GlaxoSmithKline employees as the British drug maker is accused of evading million in Chinese taxes.

  • Pharma's mega mergers not necessarily good medicine

    What we have found is that you are more productive when you have focus teams working on targets, says Scott Gottlieb, American Enterprise Institute, sharing his thoughts on big pharma deals and why they may reduce innovation and competition in the space.

  • Will Pfizer up its offer for AstraZeneca?

    Savvas Neophytou, pharmaceutical analyst at Panmure Gordon, says the probability of any further move from Pfizer on AstraZeneca has been greatly reduced as both groups disagree on the value of AstraZeneca's pipeline.